Company Ticker News

AbbVie closes deal to buy Syndesi Therapeutics for up to $1 billion

AbbVie closes deal to buy Syndesi Therapeutics for up to $1 billion


ylliX - Online Advertising Network

Shares of AbbVie ABBV, -1.18% were down 0.6% in premarket trading on Tuesday after the company completed a $1 billion acquisition of Syndesi Therapeutics SA. Syndesi is developing treatments for cognitive impairment and other symptoms associated with Alzheimer’s disease and major depressive disorder.

...read full article on Market Watch